Research-use catalog page
COA request, lot visibility, availability, and schema stay aligned.
Cagrilintide is a long-acting amylin analog (~7-day half-life) developed for once-weekly combination dosing with semaglutide — the most clinically advanced amylin compound, with Phase 3 REDEFINE data published.
Temporarily unavailable
This product is listed in the catalog, but it is not currently available for ordering. Pricing, specifications, and support details remain visible while launch availability is being finalized.
Free shipping on orders over $150
Research Supplies
Need bacteriostatic water, syringes, or an alcohol prep kit? Email us — we can bundle reconstitution supplies with your order.
Ask about a research kit →Need the COA before you order? Request it here.
In your order
Lyophilized vial
Sterile-filtered, freeze-dried peptide in glass vial, sealed under inert gas.
Lot ID on every vial
Printed lot ID ties this exact vial to its analytical record.
COA on request
Independent third-party HPLC certificate, matched to your lot, sent on request.
Carrier-tracked shipping
Shipped from a US facility with full carrier tracking and protective packaging.
The Peptific standard
Peptide quality is invisible until it isn’t. Lot identity, purity, fill integrity, and chain of custody are the difference between usable research material and wasted budget.
Third-party HPLC tested
Every lot is tested for identity and purity by an independent analytical lab. Certificate of Analysis available on request, tied to the exact lot you receive.
Lyophilized and lot-tracked
Sterile-filtered, freeze-dried, sealed under inert gas. Each vial carries its own lot ID — full chain of custody from fill to delivery.
US-based fulfillment
Orders ship from a temperature-controlled US facility with carrier tracking. No drop-shipping, no opaque overseas relay.
Real support, not a ticket queue
A real person responds to research questions, lot questions, and order questions — usually same business day. No bot triage.
How it works
Cagrilintide activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and nucleus tractus solitarius, producing satiety signals, glucagon suppression, and gastric motility effects distinct from GLP-1R pathways. C18 fatty acid modification enables ~7-day half-life for weekly dosing. REDEFINE-1 Phase 3 showed 22.7% body weight reduction in combination with semaglutide 2.4 mg.
Compound profile
Product definition
Cagrilintide is a long-acting amylin analog (~7-day half-life) developed for once-weekly combination dosing with semaglutide — the most clinically advanced amylin compound, with Phase 3 REDEFINE data published.
Cagrilintide is a synthetic amylin analog developed by Novo Nordisk. Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells, acting on calcitonin receptor/RAMP1, RAMP2, and RAMP3 complexes to modulate satiety, glucagon secretion, and gastric emptying. Cagrilintide's modifications from native amylin include structural stabilizations to prevent the aggregation propensity of native IAPP and a C18 fatty acid conjugate for albumin binding, achieving a ~7-day half-life versus native amylin's minutes-long clearance. The investigational CagriSema program combines cagrilintide with semaglutide in a fixed-ratio subcutaneous formulation. The REDEFINE Phase 3 program (REDEFINE-1, -2, -3) is the most comprehensive prospective evaluation of an amylin + GLP-1RA combination in the obesity research literature, producing the highest-powered Phase 3 dataset for amylin pharmacology published to date.
Research audience
Cagrilintide is used by researchers studying amylin receptor pharmacology, neuroendocrine satiety signaling, combination incretin strategies, obesity mechanisms, and beta cell co-secretion biology. It is the reference long-acting amylin compound for investigators requiring Phase 3-validated amylin pharmacology data.
Research context
The amylin receptor system has been under investigation since the original characterization of IAPP in the 1980s. Pramlintide (Symlin) — a short-acting amylin analog — achieved FDA approval in 2005 for adjunct therapy in T1D and T2D, establishing amylin receptor agonism as a clinically valid pharmacological approach. However, pramlintide's multiple-daily-injection requirement limited its utility. Cagrilintide represents the technical advance of applying long-acting fatty acid modification technology (previously used in semaglutide and insulin degludec) to the amylin class, enabling weekly dosing and combination with semaglutide in a single injection. The REDEFINE program was designed with the explicit hypothesis that combining two mechanistically distinct receptor systems (amylin + GLP-1R) would produce additive weight reduction beyond either alone. REDEFINE-1 results confirmed this hypothesis: 22.7% vs semaglutide alone (approx. 15%) in comparable populations, suggesting approximately 7-8 additional percentage points of weight reduction attributable to the amylin receptor component.
Common questions
You might also want to check out these products.
Cagri/Sema
$27.00
CagriSema is a fixed combination of cagrilintide (amylin analog) and semaglutide (GLP-1RA) studied in Phase 3 REDEFINE trials — 22.7% mean body weight reduction at 68 weeks, exceeding semaglutide-alone benchmarks.
Semaglutide
$16.00
Semaglutide is a GLP-1 receptor agonist with ~7-day half-life via albumin-binding fatty acid modification — the most extensively studied GLP-1RA, anchoring the SUSTAIN and STEP clinical programs.
Retatrutide
$30.00
Retatrutide is a once-weekly triple GLP-1/GIP/glucagon receptor agonist — Phase 2 data showed 24.2% mean body weight reduction at 48 weeks, the highest result in obesity pharmacology Phase 2 trial history at publication.
Tirzepatide
$25.00
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of its class, with Phase III data showing 22.5% mean body weight reduction at 72 weeks, the highest performance in obesity pharmacology trial history at publication.
Research Use Only
Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.
Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.
By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy